Overview

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Immune Checkpoint Inhibitors